​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $1,113.27, with a high of $1,292.00 and a low of $805.00. This represents a 61.98% increase from the last price of $687.27.

$650 $780 $910 $1 $1 $1 High: $1292 Avg: $1113.27 Low: $805 Last Closed Price: $687.27

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (84.62%), 4 Hold (15.38%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 4 22 Strong Sell Sell Hold Buy Strong Buy

REGN Forecast vs Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals61.98%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-430
Avg Price Target-$1.11K$1.15K
Last Closing Price$687.27$687.27$687.27
Upside/Downside-61.33%67.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 257128-128
Dec, 247127-127
Nov, 24812121235
Oct, 24814121237
Sep, 24814121136
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 01, 2024Evan David SeigermanBMO Capital$1.19K$843.6041.06%73.15%
Nov 01, 2024Christopher RaymondPiper Sandler$1.20K$843.6041.65%73.88%
Nov 01, 2024Andrew BerensLeerink Partners$880.00$843.604.31%28.04%
Oct 31, 2024Cory KasimovEvercore ISI$1.17K$838.2039.58%70.24%
Oct 24, 2024Cory KasimovEvercore ISI$1.18K$941.3924.82%70.97%
Oct 23, 2024Mohit BansalWells Fargo$1.05K$962.349.11%52.78%
Sep 24, 2024Thomas KleeTruist Financial$1.20K$1.09K9.89%74.60%
Sep 24, 2024David RisingerLeerink Partners$1.08K$1.09K-1.37%56.71%
Sep 24, 2024Brian SkorneyRobert W. Baird$940.00$1.09K-13.92%36.77%
Sep 24, 2024Salveen RichterGoldman Sachs$1.29K$1.09K18.32%87.99%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024CitigroupNeutralinitialise
Nov 01, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 29, 2024Piper SandlerOverweightOverweighthold
Oct 24, 2024Evercore ISIOutperformOutperformhold
Oct 23, 2024SusquehannaNeutralNeutralhold
Oct 23, 2024Cowen & Co.BuyBuyhold
Oct 23, 2024Wells FargoOverweightOverweighthold
Oct 04, 2024Wells FargoMarket PerformMarket Performhold
Sep 27, 2024Cowen & Co.BuyBuyhold
Sep 25, 2024Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$25 $36 $47 $58 $69 $80 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$32.65$76.40$40.51$37.05-----
Avg Forecast$30.33$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$28.62$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Low Forecast$31.59$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Surprise %7.65%6.82%-4.91%-13.07%-----

Revenue Forecast

$5B $8B $11B $14B $17B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.50B$16.07B$12.17B$13.12B-----
Avg Forecast$8.50B$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$8.13B$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Low Forecast$8.77B$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Surprise %0.00%2.39%2.62%1.37%-----

Net Income Forecast

$2B $3B $5B $6B $8B $9B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.51B$8.08B$4.34B$3.95B-----
Avg Forecast$2.99B$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$2.39B$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Low Forecast$3.59B$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Surprise %17.57%10.75%-3.36%------

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 26 Wall Street analysts, averages $1.11K over the next 12 months. The price target range spans from $805 at the low end to $1.29K at the high end, suggesting a potential 61.98% change from the previous close price of $687.27.

How does Regeneron Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Regeneron Pharmaceuticals stock forecast shows a 61.98% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • January 2025: 25.00% Strong Buy, 42.86% Buy, 28.57% Hold, 0% Sell, 3.57% Strong Sell.
  • December 2024: 25.93% Strong Buy, 44.44% Buy, 25.93% Hold, 0% Sell, 3.70% Strong Sell.
  • November 2024: 22.86% Strong Buy, 34.29% Buy, 34.29% Hold, 2.86% Sell, 5.71% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 45.02 for 2024, a 21.51% increase from the reported $37.05 in 2023. The prediction for 2025 is $44.51, $48.41 for 2026, $56.23 for 2027, and $61.14 for 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $14.18B for 2024, a 8.11% increase from the reported $13.12B in 2023. The forecast for 2025 is $14.63B, $15.52B for 2026, $17.22B for 2027, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Regeneron Pharmaceuticals's average annual net income forecast is $5.15B for 2024, reflecting an 30.20% increase from the reported $3.95B in 2023. The projection for 2025 is $4.36B, $4.65B for 2026, $5.3B for 2027, and $6.95B for 2028.